|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.08 USD | -0.52% |
|
+2.41% | -22.07% |
| 05-16 | Collegium Pharmaceutical, Inc. Announces Appointment of Michael Donovan as Director | CI |
| 05-12 | Collegium completes acquisition of Azstarys® from Corium Therapeutics | RE |
Company Valuation: Collegium Pharmaceutical, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 650 | 778.9 | 1,004 | 924 | 1,464 | 1,170 | - | - |
| Change | - | 19.82% | 28.87% | -7.95% | 58.4% | -20.05% | - | - |
| Enterprise Value (EV) 1 | 650 | 778.9 | 1,004 | 924 | 1,464 | 1,921 | 1,498 | 1,170 |
| Change | - | 19.82% | 28.87% | -7.95% | 58.4% | 31.26% | -22.03% | -21.88% |
| P/E | 10x | -31.4x | 23.9x | 15.4x | 26.8x | 13.6x | 9.67x | - |
| PBR | - | - | - | - | - | 3.3x | 2.33x | - |
| PEG | - | 0x | -0x | 0.3x | -3.83x | 0.3x | 0.2x | - |
| Capitalization / Revenue | 2.35x | 1.68x | 1.77x | 1.46x | 1.88x | 1.34x | 1.35x | 1.4x |
| EV / Revenue | 2.35x | 1.68x | 1.77x | 1.46x | 1.88x | 2.2x | 1.73x | 1.4x |
| EV / EBITDA | 5.49x | 2.93x | 2.74x | 2.3x | 3.18x | 3.96x | 3.41x | 3.23x |
| EV / EBIT | 36.9x | 23.4x | 6.01x | 5.44x | 8.15x | 4.05x | 3.45x | 3x |
| EV / FCF | - | - | 3.66x | 4.54x | 4.47x | 6.1x | 3.56x | - |
| FCF Yield | - | - | 27.3% | 22% | 22.4% | 16.4% | 28.1% | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.86 | -0.74 | 1.29 | 1.86 | 1.73 | 2.66 | 3.73 | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 276.9 | 463.9 | 566.8 | 631.4 | 780.6 | 872.9 | 866 | 833.9 |
| EBITDA 1 | 118.3 | 266 | 367 | 401.2 | 460.5 | 484.5 | 438.6 | 362.7 |
| EBIT 1 | 17.63 | 33.32 | 167 | 169.9 | 179.6 | 474.5 | 434.5 | 389.7 |
| Net income 1 | 71.52 | -25 | 48.16 | 69.19 | 62.87 | 108.2 | 158.3 | - |
| Net Debt 1 | - | - | - | - | - | 750.9 | 327.7 | - |
| Reference price 2 | 18.68 | 23.20 | 30.78 | 28.65 | 46.30 | 36.08 | 36.08 | 36.08 |
| Nbr of stocks (in thousands) | 34,797 | 33,572 | 32,611 | 32,250 | 31,611 | 32,434 | - | - |
| Announcement Date | 24/02/22 | 23/02/23 | 22/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 13.56x | 2.2x | 3.96x | - | 1.17B | |
| 35.04x | 12.53x | 26.21x | 0.57% | 1,051B | |
| 27.19x | 6.2x | 16.98x | 2.12% | 609B | |
| 33.15x | 7.52x | 15.43x | 2.7% | 450B | |
| 17.85x | 4.43x | 10.91x | 3% | 330B | |
| 21.66x | 5.55x | 13.44x | 2.84% | 284B | |
| 21.16x | 4.46x | 12.34x | 1.97% | 263B | |
| 14.44x | 5.41x | 11.14x | 3.44% | 223B | |
| 24.02x | 6.35x | 11.22x | 2.75% | 198B | |
| -48.37x | 5.78x | 31.95x | 2.42% | 167B | |
| Average | 15.97x | 6.04x | 15.36x | 2.42% | 357.62B | |
| Weighted average by Cap. | 24.01x | 7.82x | 18.33x | 2% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- COLL Stock
- Valuation Collegium Pharmaceutical, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
